HK1022918A1 - Modified tnfalpha molecules, dna encoding such modified tnfalpha molecules and vaccines comprising such modified tnfalpha molecules and dna - Google Patents

Modified tnfalpha molecules, dna encoding such modified tnfalpha molecules and vaccines comprising such modified tnfalpha molecules and dna

Info

Publication number
HK1022918A1
HK1022918A1 HK00101819A HK00101819A HK1022918A1 HK 1022918 A1 HK1022918 A1 HK 1022918A1 HK 00101819 A HK00101819 A HK 00101819A HK 00101819 A HK00101819 A HK 00101819A HK 1022918 A1 HK1022918 A1 HK 1022918A1
Authority
HK
Hong Kong
Prior art keywords
tnfalpha
modified
molecules
human
molecule
Prior art date
Application number
HK00101819A
Other languages
English (en)
Inventor
Martin Roland Jensen
Iben Dalum
Soren Mouritsen
Henrik Elsner
Original Assignee
Harmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harmexa As filed Critical Harmexa As
Publication of HK1022918A1 publication Critical patent/HK1022918A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/144—Tumor necrosis factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK00101819A 1997-04-15 2000-03-23 Modified tnfalpha molecules, dna encoding such modified tnfalpha molecules and vaccines comprising such modified tnfalpha molecules and dna HK1022918A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK41897 1997-04-15
US4418797P 1997-04-24 1997-04-24
PCT/DK1998/000157 WO1998046642A1 (en) 1997-04-15 1998-04-15 MODIFIED TNFα MOLECULES, DNA ENCODING SUCH MODIFIED TNFα MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNFα MOLECULES AND DNA

Publications (1)

Publication Number Publication Date
HK1022918A1 true HK1022918A1 (en) 2000-08-25

Family

ID=8093298

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00101819A HK1022918A1 (en) 1997-04-15 2000-03-23 Modified tnfalpha molecules, dna encoding such modified tnfalpha molecules and vaccines comprising such modified tnfalpha molecules and dna

Country Status (30)

Country Link
US (1) US7118750B1 (ru)
EP (1) EP0975668B1 (ru)
JP (1) JP2001521386A (ru)
KR (1) KR100522289B1 (ru)
CN (1) CN1178955C (ru)
AR (1) AR012427A1 (ru)
AT (1) ATE326481T1 (ru)
AU (1) AU743400B2 (ru)
BR (1) BR9811462A (ru)
CA (1) CA2289476A1 (ru)
CZ (1) CZ9903657A3 (ru)
DE (1) DE69834556T2 (ru)
DK (1) DK0975668T3 (ru)
EE (1) EE9900461A (ru)
ES (1) ES2264569T3 (ru)
HK (1) HK1022918A1 (ru)
HR (1) HRP980203B1 (ru)
HU (1) HUP0001930A3 (ru)
IL (1) IL132281A0 (ru)
NO (1) NO995002L (ru)
NZ (1) NZ337955A (ru)
PL (1) PL194221B1 (ru)
RU (1) RU2241715C2 (ru)
SI (1) SI0975668T1 (ru)
SK (1) SK285639B6 (ru)
TR (1) TR199902562T2 (ru)
TW (1) TW510921B (ru)
UA (1) UA72440C2 (ru)
WO (1) WO1998046642A1 (ru)
ZA (1) ZA983148B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
DE60045240D1 (de) * 1999-03-02 2010-12-30 Centocor Inc Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
AU778470B2 (en) 1999-07-20 2004-12-09 Pharmexa A/S Method for down-regulating GDF-8 activity
AU2001265830A1 (en) * 2000-06-21 2002-01-02 Ferring, B.V. Solubilised protein vaccines
EP1485122A2 (en) * 2002-03-11 2004-12-15 Pharmexa A/S Novel application of vaccination against tnf-alpha
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
EP1594969B1 (en) * 2003-02-01 2015-05-20 Janssen Sciences Ireland UC Active immunization to generate antibodies to soluble a-beta
CN1960744A (zh) * 2004-02-27 2007-05-09 瓦克斯咨询公司 肽IL1β和TNFα以及应用其治疗的方法
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
TWI399384B (zh) 2005-05-16 2013-06-21 Abbott Biotech Ltd ＴＮＦα抑制劑於治療侵蝕型多發性關節炎之用途
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
KR20100084623A (ko) * 2007-09-25 2010-07-27 인터벳 인터내셔널 비.브이. 골관절염 치료용 백신
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
KR20120101050A (ko) 2009-11-05 2012-09-12 더 유에이비 리서치 파운데이션 기저형 유전자형 암의 치료 방법
WO2011116344A2 (en) 2010-03-18 2011-09-22 The Uab Research Foundation Targeting cancer stem cells
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
BR112013014302A2 (pt) 2010-12-08 2016-09-20 Neovacs vacina fortemente inativada e ainda altamente imunogênica e processo de fabricação da mesma
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
CN102539778A (zh) * 2010-12-24 2012-07-04 北京义翘神州生物技术有限公司 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒
JP2011201902A (ja) * 2011-05-19 2011-10-13 Wyeth Llc 可溶性Ａ−βに対する抗体を生成させるための能動免疫
CN103376327A (zh) * 2012-04-28 2013-10-30 通用电气公司 检测抗体或融合蛋白的浓度的方法
EP3292140B1 (en) 2015-05-05 2022-04-20 Rubicon Biotechnology LLC Cancer immunotherapeutic
CN106279403B (zh) * 2016-08-16 2019-06-11 长春市海兰深生物医学技术有限公司 一种检测天然肺癌相关抗体的组合物、试剂盒和方法
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3750056T2 (de) 1986-06-20 1995-04-06 Dainippon Pharmaceutical Co Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS.
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU634379B2 (en) 1991-04-29 1993-02-18 Csl Limited Recombinant immunocastration vaccine
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
CA2119089A1 (en) 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden

Also Published As

Publication number Publication date
NO995002L (no) 1999-12-15
TR199902562T2 (xx) 2000-02-21
SK140999A3 (en) 2000-06-12
CN1252809A (zh) 2000-05-10
HRP980203A2 (en) 1998-12-31
EP0975668A1 (en) 2000-02-02
KR100522289B1 (ko) 2005-10-19
ZA983148B (en) 1999-10-15
US7118750B1 (en) 2006-10-10
TW510921B (en) 2002-11-21
KR20010006416A (ko) 2001-01-26
SK285639B6 (sk) 2007-05-03
AR012427A1 (es) 2000-10-18
CN1178955C (zh) 2004-12-08
EE9900461A (et) 2000-06-15
HUP0001930A2 (hu) 2000-09-28
AU743400B2 (en) 2002-01-24
PL194221B1 (pl) 2007-05-31
DE69834556T2 (de) 2007-05-10
NZ337955A (en) 2000-09-29
CA2289476A1 (en) 1998-10-22
JP2001521386A (ja) 2001-11-06
CZ9903657A3 (cs) 2001-09-12
ES2264569T3 (es) 2007-01-01
EP0975668B1 (en) 2006-05-17
DK0975668T3 (da) 2006-09-25
NO995002D0 (no) 1999-10-14
AU7030398A (en) 1998-11-11
UA72440C2 (en) 2005-03-15
SI0975668T1 (sl) 2007-02-28
PL336295A1 (en) 2000-06-19
HUP0001930A3 (en) 2001-10-29
RU2241715C2 (ru) 2004-12-10
IL132281A0 (en) 2001-03-19
DE69834556D1 (de) 2006-06-22
HRP980203B1 (en) 2003-04-30
ATE326481T1 (de) 2006-06-15
WO1998046642A1 (en) 1998-10-22
BR9811462A (pt) 2000-09-12

Similar Documents

Publication Publication Date Title
HK1022918A1 (en) Modified tnfalpha molecules, dna encoding such modified tnfalpha molecules and vaccines comprising such modified tnfalpha molecules and dna
BG102343A (en) Recombinant anti-cd4 antibodies for therapy in hyman medicine
NZ508381A (en) Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
EP0651818A4 (en) IMMUNOGENIC PEPTIDES, ANTIBODIES AND USES THEREOF IN CONNECTION WITH THE BINDING OF THE CD4 MOLECULE RECEPTOR.
IL152507A0 (en) Methods and compositions for impairing multiplication of hiv-1
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
NO20011381L (no) Preparater av streptokokk C<beta>-protein
BR9408006A (pt) Molécula de ácido nucléico isolada e purificada vetor e vetor de express o adaptados para transformaçao de hospedeiro hospedeiro transformado proteina receptora "transferrin" recombinante ou fragmento ou análogo da mesma proteina Tbpl purificada e isolada proteina Tbp2 purificada e isolada peptídeo composiç o imunogênica vetor ativo para fornecimento de proteina receptora "transferrin" vetor de plasmideo linhagem de haemophilus processo para produzir proteina Tbp2 ou Tbpl purificada e isolada
AU2759895A (en) Recombinant allergen, fragments thereof, corresponding recombinant dna molecules, vectors and hosts containing the dna molecules, diagnostic and therapeutic uses of said allergens and fragments
IL93397A (en) Pancreatic islet cell antigen protein or peptides, their preparation by molecular cloning, their use in the diagnosis of insulin dependent diabetes mellitus and pharmaceutical compositions comprising said antigens
CA2270176A1 (en) Methylated, smd homologous peptides, reactive with the antibodies from sera of living beings affected with systemic lupus erythematosus
AU6517400A (en) 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
AU5776799A (en) Modified hcv peptide vaccines
PT93178B (pt) Agente proteico anticanceroso
EP1277837A3 (de) Epididymis-spezifische DNA-Sequenzen und deren Verwendung
NZ507983A (en) A polypeptide comprising the amino acid of an n- terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
CA2006587A1 (en) Membrane proteins and peptides of haemophilus influenzae type b
KR930703444A (ko) 어류 황체화 호르몬-방출 호르몬 동족체
AU2001281943A1 (en) The t-cell protein (tzon7), peptides and antibodies derived therefrom and uses thereof
NZ505350A (en) DNA encoding a tumour antigen peptide (43 kDa) for diagnosis or treatment of tumours
AU2001251410A1 (en) 12303, a novel human twik molecule and uses thereof
WO2002010379B1 (en) Modified cea and uses thereof
AU2001288284A1 (en) 14189, a human kinase and uses thereof
AR036104A1 (es) Un receptor acoplado a la proteina g, gave3
HUP0001462A2 (en) Human toll-like receptor proteins, related reagents and methods

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100415